{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:34:22Z","timestamp":1770503662788,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.euroneuro.2008.02.004","type":"journal-article","created":{"date-parts":[[2008,3,16]],"date-time":"2008-03-16T11:42:50Z","timestamp":1205667770000},"page":"S108-S114","source":"Crossref","is-referenced-by-count":54,"special_numbering":"S2","title":["Prolactin awareness: An essential consideration for physical health in schizophrenia"],"prefix":"10.1016","volume":"18","author":[{"given":"Angel L.","family":"Montejo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2008.02.004_bib1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4088\/JCP.v65n0918f","article-title":"Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report","volume":"65","author":"Anghelescu","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0006-3223(94)91164-9","article-title":"A pilot study of a structured interview addressing sexual function in men with schizophrenia","volume":"35","author":"Burke","year":"1994","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","article-title":"Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics","volume":"21","author":"Bushe","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","article-title":"Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine","volume":"189","author":"Chrzanowski","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1677\/joe.0.1570187","article-title":"Prolactin receptor signal transduction in cells of the immune system","volume":"157","author":"Clevenger","year":"1998","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib9","first-page":"143","article-title":"Antipsychotic-induced hyperprolactinemia and sexual dysfunction","volume":"36","author":"Compton","year":"2002","journal-title":"Psychopharmacol. Bull."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2008.02.004_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00113-0","article-title":"Sexual dysfunction and antipsychotic treatment","volume":"28","author":"Cutler","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/schbul\/sbl037","article-title":"A case series: evaluation of the metabolic safety of aripiprazole","volume":"33","author":"De Hert","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1176\/ajp.156.1.142","article-title":"Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior","volume":"156","author":"Dorevitch","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4088\/JCP.v67n0420c","article-title":"High-dose aripiprazole in treatment-resistant schizophrenia","volume":"67","author":"Duggal","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00005053-198208000-00004","article-title":"Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients","volume":"170","author":"Ghadirian","year":"1982","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2265.1996.00799.x","article-title":"Prolactin and growth hormone receptors.","volume":"45","author":"Goffin","year":"1996","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib17","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","article-title":"Risk of hip fracture in patients with a history of schizophrenia","volume":"190","author":"Howard","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1176\/appi.ajp.158.2.311","article-title":"Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":"A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) Study","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur. Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.euroneuro.2008.02.004_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":"Prolactin levels and adverse events in patients treated with risperidone","volume":"19","author":"Kleinberg","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.euroneuro.2008.02.004_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0306-4530(02)00130-0","article-title":"What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?","volume":"28","author":"Knegtering","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.jcp.0000106220.36344.04","article-title":"A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning","volume":"24","author":"Knegtering","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib25","first-page":"61","article-title":"Endocrine side effects among psychiatric patients treated with antipsychotics","volume":"8","author":"Kovacs","year":"2006","journal-title":"Neuropsychopharmacol. Hung."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2265.1979.tb02093.x","article-title":"Prolactin concentrations in normal menstrual cycles and conception cycles","volume":"10","author":"Lenton","year":"1979","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib27","first-page":"56","article-title":"Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences","volume":"63","author":"Maguire","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib29","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib30","first-page":"851","article-title":"Management of psychotropic-induced hyperprolactinemia","volume":"11","author":"Marken","year":"1992","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","article-title":"Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia","volume":"184","author":"Meaney","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0165-1781(83)90002-1","article-title":"Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis","volume":"9","author":"Meltzer","year":"1983","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0165-1781(83)90001-X","article-title":"Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response","volume":"9","author":"Meltzer","year":"1983","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1471-0528.1988.tb12798.x","article-title":"A randomized trial of the use of cocaine spray to provide pain relief during laser vaporization of the cervix","volume":"95","author":"Mikhail","year":"1988","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0889-8529(05)70203-6","article-title":"Disorders of prolactin secretion","volume":"30","author":"Molitch","year":"2001","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/01.jcp.0000186872.04984.56","article-title":"A 6-month prospective observational study on the effects of quetiapine on sexual functioning","volume":"25","author":"Montejo Gonzalez","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib38","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.4088\/JCP.v67n1112","article-title":"Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial","volume":"67","author":"Perlis","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.163.2.217","article-title":"Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","volume":"163","author":"Perlis","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-3223(94)91147-9","article-title":"Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia","volume":"35","author":"Rao","year":"1994","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib42","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":"Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial","volume":"162","author":"Schooler","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib43","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/bjp.181.1.49","article-title":"Sexual dysfunction in patients taking conventional antipsychotic medication","volume":"181","author":"Smith","year":"2002","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4088\/JCP.v62n1101","article-title":"Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, \u201cGoldilocks\u201d actions at dopamine receptors","volume":"62","author":"Stahl","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2006.16.317","article-title":"The effect of long-term antipsychotic treatment on prolactin","volume":"16","author":"Staller","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib47","doi-asserted-by":"crossref","unstructured":"Stampfer, M.J., Colditz, G.A. and Willett, W.C. (1990) Menopause and heart disease. A review. Ann N Y Acad Sci 592, 193\u2013203; discussion 257\u2013262.","DOI":"10.1111\/j.1749-6632.1990.tb30329.x"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.regpep.2004.08.008","article-title":"Physiological roles of prolactin-releasing peptide","volume":"126","author":"Sun","year":"2005","journal-title":"Regul. Pept."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib49","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1592\/phco.26.6.748","article-title":"Atypical antipsychotics and pituitary tumors: a pharmacovigilance study","volume":"26","author":"Szarfman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib50","series-title":"Current Psychotherapeutic Drugs","author":"Tandon","year":"1998"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00024677-200302010-00003","article-title":"Hyperprolactinemia: pathophysiology and management","volume":"2","author":"Verhelst","year":"2003","journal-title":"Treat. Endocrinol."},{"key":"10.1016\/j.euroneuro.2008.02.004_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib53","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer","volume":"59","author":"Wang","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000119265","article-title":"Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology","volume":"33","author":"Windgassen","year":"1996","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2008.02.004_bib55","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000067769","article-title":"A case-control study of endometrial cancer after antipsychotics exposure in premenopausal women","volume":"64","author":"Yamazawa","year":"2003","journal-title":"Oncology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X08000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X08000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T02:34:16Z","timestamp":1684290856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X08000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":55,"alternative-id":["S0924977X08000473"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2008.02.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}